Foundation Medicine is an example of the right people coming together at the right place and the right time with an important vision. Our management team has a breadth of experience in medical practice, life sciences, genomics, pharmaceuticals, biotechnology, and the clinical diagnostics and laboratory industriesas well as a world-class track record in building successful organizations in the field.
Chief Executive Officer
Troy Cox joined Foundation Medicine in 2017 as its Chief Executive Officer. He’s driven by improving the lives of patients. Prior to joining Foundation Medicine, Troy served as Senior Vice President and Officer at Genentech, where he led US BioOncology, the #1 Oncology Company fueled by over 1,500 people passionately delivering for patients. He serves on the boards of Dream Foundation and the Healthcare Businesswomen’s Association (H.B.A) San Francisco Chapter.
Troy joined Genentech in February 2010. Prior to taking BioOncology leadership in 2013, he led diverse in-market specialty and primary care franchises as well as US market preparation for 6 new medicines. Further, he was selected to lead the worldwide launch readiness for two high priority launches. Troy has over 25 years of extensive and diverse BioPharma experience and has contributed to over 20 product launches. Before coming to Genentech, Troy had global P&L responsibility for Specialty Commercial Operations including Sales, Marketing, and Medical Affairs at UCB BioPharma. Prior to UCB, Troy led a large US Primary Care Business Unit for Sanofi-Aventis. He also led Global Marketing and Medical for Anti-Infectives at Aventis. Troy’s diverse experience includes senior roles in European Country General Management, US Managed Care Sales Leadership, and US Claritin Marketing with Schering-Plough. His pharmaceutical career began as a Sales Representative after earning his MBA at the University of Missouri. He also received a BBA in Finance from the University of Kentucky.
President and Chief Operating Officer
Dr. Kafka joined Foundation Medicine in January 2013, bringing over 15 years of business and strategy experience in the pharmaceutical and biotechnology industries, with a focus on targeted therapies in oncology. Dr. Kafka was previously chief operating officer and chief financial officer at Aileron Therapeutics, where he led the company's operations, finance, and human resources functions.
"I believe we are at the tip of the iceberg in understanding how molecular information can help us to get better drugs to the market faster, and giving physicians and patients the relevant information they need to make treatment decisions."
Before this, Dr. Kafka was vice president of finance at Infinity Pharmaceuticals (NASDAQ: INFI) where he led finance, investor and public relations and business operations. While at Infinity, he worked on a number of innovative collaborations with leading pharmaceutical companies, including the company's strategic alliance with Purdue Pharmaceuticals. Earlier in his career, Dr. Kafka was senior director of finance at Millennium Pharmaceuticals, where he was a key member of the product team in driving strategic planning and alliance management efforts with partner Johnson & Johnson for VELCADE®, a novel targeted cancer therapeutic.
Dr. Kafka earned his Ph.D. from Harvard University and his B.A. with Distinction and Honors from Stanford University.
Chief Business Officer & Head, Biopharma
Ms. Nallicheri joined Foundation Medicine in October 2016 as chief business officer and head, Biopharma. She brings with her more than 25 years of experience in corporate strategy and business development, deep knowledge across healthcare sectors in the U.S. and internationally, as well as experience building advanced analytics capabilities. She has a track record of helping grow businesses and building high-performing teams.
Prior to joining Foundation Medicine, Ms. Nallicheri was senior vice president, corporate strategy and business development, McKesson Distribution Solutions and McKesson Data & Analytics. At McKesson, she was responsible for identifying growth opportunities and working closely with the executive committee and operating team to drive business growth, financial performance and strategy execution. During her tenure at McKesson, she advanced key strategic priorities, including evolving McKesson’s North American specialty, biosimilars and manufacturer services, pricing model and retail pharmacy strategy.
Before this, Ms. Nallicheri was senior vice president, corporate development at Geron Corporation where she was a member of the executive management team and responsible for corporate strategy and business development. Earlier in her career, she was a partner and senior member of the global health practice at Booz & Company/Booz Allen Hamilton.
She has held board positions at the American Red Cross Bay Area Chapter, Bay Area Council and Healthcare Business Women’s Association.
Ms. Nallicheri earned her MBA with honors from Columbia Business School, earning beta gamma sigma designation, and her MS in business and economics from WHU Otto Beisheim School of Corporate Management in Koblenz, Germany.
Chief Information Officer
Mr. Godden joined Foundation Medicine in December 2015 as its chief information officer. In this role, Mr. Godden provides expert leadership for the company’s information technology (IT) infrastructure to support its global expansion initiatives. Mr. Godden also provides strategic oversight and creative counsel towards the company’s efforts to develop innovative customer-facing technology and decision support solutions.
Prior to joining Foundation Medicine, Mr. Godden spent more than a decade at Wolters Kluwer (WK), a $4 billion information services and publishing business located in Amsterdam. During his time at WK, Mr. Godden held various roles of increasing responsibility, most recently serving as head of Global Technology Strategy and Chief Architect. In this role, he was responsible for coordination and management of IT strategy across more than 30 global business units, the migration of WK’s core platform to a cloud-based offering, and the creation of a new program management office. Prior to this global role, Mr. Godden served as chief information officer of WK’s Pharma Solutions business where he led a staff of more than 500 individuals globally and established an agile-based development model and culture. Prior to WK, Mr. Godden held senior development positions at JDA Software and Pegasus Solutions.
Mr. Godden holds a BS degree in political science and history from Arizona State University.
Chief Medical Officer
Dr. Miller joined Foundation Medicine in October 2011 after nearly 20 years at Memorial Sloan-Kettering Cancer Center where he served as an Attending Physician. His work in clinical and translational research in lung cancer culminated in observations and collaborative efforts critical to identification of EGFR sensitizing and resistance mutations. He is considered a world's expert in lung cancer and clinical trial design and interpretation. Dr. Miller has authored and co-authored numerous abstracts, reviews, and peer-reviewed articles, which have appeared in such journals as Proceedings of the National Academy of Science USA, Cancer Research, Clinical Cancer Research and the Journal of Clinical Oncology.
Dr. Miller has received the prestigious American Cancer Society Clinical Oncology Career Development Award and the Louise and Allston Boyer Award, and was most recently recognized by the Bonnie J. Addario Lung Cancer Foundation with the 2011 Thierry Jahan "A Breath Away from the Cure" award for his efforts and contributions to lung cancer research. He is a Fellow of the American College of Physicians and a Member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
Dr. Miller, a National Merit Scholar, received a BA in mathematics at the University of Pennsylvania, where he was honored as a Benjamin Franklin Scholar, and an MD at the University of Medicine and Dentistry of New Jersey in Newark. He completed an internship and residency, and then served as Chief Medical Resident in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, and subsequently a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center.
Chief Financial Officer
Mr. Ryan joined Foundation Medicine in May 2011 and brings over 12 years of financial and operations experience in emerging life science companies. Prior to joining Foundation Medicine, Mr. Ryan led the finance and strategic planning functions of Taligen Therapeutics (acquired by Alexion Pharmaceuticals), Codon Devices, and Genomics Collaborative (acquired by SeraCare Life Sciences). He began his career at Deloitte & Touche.
Mr. Ryan holds a BS in economics from Bates College and an MBA from Babson College, and earned his CPA in Massachusetts.
Senior Vice President & General Counsel
Mr. Hesslein joined Foundation Medicine as Senior Vice President and General Counsel in June 2012, bringing over 30 years of experience in building and leading legal organizations. Mr. Hesslein was most recently senior vice president / deputy general counsel at Genzyme Corporation (acquired by Sanofi in April 2011). He served Genzyme in increasingly senior roles for 16 years, helping to establish one of the strongest business law teams in the industry and managing the legal support for many of Genzyme's most significant transactions. Mr. Hesslein also created and led Genzyme's legal support outside of the United States.
Prior to his tenure with Genzyme, Mr. Hesslein was second vice president / counsel at The New England, a mutual life insurance corporation, where he was responsible for general corporate support for all investment activities. Mr. Hesslein began his legal career at Csaplar & Bok, a Boston based law firm. In 12 years of private practice (4 years as a partner), Mr. Hesslein assisted in the early growth of the firm and co-founded the firm's Philadelphia office.
Mr. Hesslein earned a BA from Yale University and received his JD from The Cornell Law School.
Chief Commercial Officer & GM, Clinical Oncology Solutions
Dave Daly joined Foundation Medicine in December 2014 with more than two decades of results-driven commercial diagnostics expertise and a demonstrated track record in building brands and accelerating product adoption in key markets around the world.
Dave served most recently as vice president, commercial operations, Anatomic Pathology Division at Thermo Fisher Scientific. He joined Thermo Fisher Scientific following Thermo's acquisition of Life Technologies where he served as Head of Oncology, Medical Sciences. Prior to Life Technologies, Dave held a variety of leadership roles for Clarient, Inc., ultimately serving as its chief commercial officer. During his Clarient tenure, he delivered multiple successive years of annual sales growth, exceeding sales quotas and supporting the successful acquisition of Clarient by GE Healthcare. Prior to Clarient /GE Healthcare, Dave served in various sales and marketing leadership roles in molecular diagnostics, hematology, and laboratory automation with Roche Diagnostics and Abbott Laboratories.
Dave holds a Bachelor of Arts degree and a Master's degree in economics from the University of California, Irvine and Santa Barbara, respectively.
Senior Vice President, Corporate Communications and Government Affairs
Ms. Hager joined Foundation Medicine in December 2014, bringing more than 15 years of strategic marketing, corporate and financial communications expertise in the life sciences industry to her role at Foundation Medicine. Her experience includes strategic communications in support of corporate and product brands, strategic financings and acquisitions, and regulatory actions.
Prior to joining Foundation Medicine, Ms. Hager previously served as Senior Vice President of Corporate Communications and Government Affairs for Myriant Corporation, an emerging industrial biotech company focused on the development of renewable chemicals. In this role, she successfully led all corporate, financial and advocacy communications efforts, including leading the development of new legislation, tax policy initiatives and public-private partnerships to support broad commercialization of bio-based chemicals in the United States. Before that, Ms. Hager served in a number of leadership roles with several biotech companies including Vice President of Corporate Communications and Investor Relations for Targanta (sold to The Medicines Company) and Vice President of Corporate Communications, Investor Relations and Corporate Development for Coley Pharmaceutical (sold to Pfizer). Ms. Hager's communications experience also includes leadership roles at Bayer, where she served as Senior Manager of Global Strategic Marketing Communications for the company's Diagnostics Division and later, as Senior Manager of Global Communications and Public Relations for Bayer HealthCare Worldwide. Ms. Hager also served as a Director of the Corporate and Investor Relations Practice at W2O, a global healthcare communications agency, where she championed the development and execution of strategic communications programs for publicly traded biopharma companies in the United States and Europe.
Ms. Hager holds a Bachelor of Science degree with honors in Biology and a Master's degree in Business Administration from Northeastern University.
Head of Product Development
Michael Doherty has been Head of Product Development at Foundation Medicine since the beginning of 2017. In this role, he leads a team dedicated to the introduction of clinical and data products in the field of cancer genomics based on Next-Generation Sequencing.
Prior to this he was Head of Regulatory Affairs at Roche Pharmaceuticals and Genentech for a period of 14 years from 2002 to 2016, overseeing the approvals of products in the field of oncology, immunology, hematology and bone disease. During his career, he has worked in Regulatory Affairs in Pharmaceutical Companies based in the UK, France, Switzerland and the US.
In addition, he spent 2 years at Genentech building a new organization called Strategic Innovation which was charged with identifying and deploying disruptive concepts in the field of drug development.
Today, Michael also serves as a Strategic Adviser to Genentech Product Development and as a Regulatory Strategy Adviser to VisionGate, a clinical stage cancer diagnostics and therapeutics company. He also serves on the advisory board of IBM Watson Life Sciences.
Prior to working in the Pharmaceutical Industry, Michael worked at the University of Manchester, UK, and Christie Hospital in the Regional Endocrinology Laboratory. He has a BSc in Biochemistry (University of Reading, UK) and a fellowship of the Institute of Medical Sciences, UK, and a Diploma in Management Studies from the University of Portsmouth, UK.